Terbutaline, the key component of Bricanyl, works by stimulating β2-adrenergic receptors in the lungs. This leads to the relaxation of bronchial muscles and an opening of the airways, providing quick relief from bronchospasm and improving airflow to the lungs. The medication can be administered in various forms, including tablets, inhalers, and solution forms for nebulizers, catering to the different needs and preferences of patients with respiratory conditions.

The medication’s active component, brimonidine tartrate, targets the alpha-2 adrenergic receptors found within the eye. Doing so diminishes the secretion of aqueous humor and simultaneously augments uveoscleral outflow. These effects collaborate to decrease intraocular pressure. As a preferential treatment option for patients with open-angle glaucoma or ocular hypertension, Brimonidine P’s direct ocular activity significantly limits the risk of systemic side effects, endorsing its suitability for ongoing therapy management of these eye conditions.

The active compound budesonide directly targets the inflammation process at the cellular level. It helps to prevent the release of substances in the body that cause inflammation, effectively managing symptoms of wheezing and shortness of breath in asthma patients and providing relief in gastrointestinal disorders like Crohn’s disease and ulcerative colitis. Due to its targeted action and local application (especially when inhaled or used nasally), budesonide tends to have fewer systemic side effects than other corticosteroids.